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S U M M A R Y
Objectives: To avoid the use of carbapenems, alternatives such as cephamycin, piperacillin–tazobactam,
and others are suggested for the treatment of extended-spectrum beta-lactamase-producing
Enterobacteriaceae (ESBL-PE) infections. The aim of this study was to evaluate the frequency and the
feasibility of antimicrobial de-escalation for ESBL-PE-related infections.
Methods: A prospective observational, bi centric cohort study was conducted. All patients with ESBL-PE
infections were included. De-escalation was systematically suggested if patients were clinically stable
and the isolate was susceptible to possible alternatives.
Results: Seventy-nine patients were included: 36 (45.6%) were children, 27 (34.1%) were hospitalized in
intensive care units, and 37 (47%) were immunocompromised. Urinary tract infections, pneumonia, and
catheter-related bloodstream infections accounted for 45.6%, 19%, and 10%, respectively, of the cohort.
Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were the three most frequent causative
organisms isolated. On day 5, 47 (59.2%) of the patients were still receiving carbapenems. Antimicrobial
resistance (44.7%), infection relapse (26.9%), and clinical instability (19.2%) were the most important
reasons for not prescribing alternatives. E. coli-related infections appeared to be a protective factor
against maintaining the carbapenem prescription (odds ratio 0.11, 95% conﬁdence interval 0.041–0.324;
p = 0.0013).
Conclusions: In clinical practice, less than 50% of patients with ESBL-PE-related infections were de-
escalated after empirical treatment with carbapenems.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Since the 1980s, extended-spectrum beta-lactamase (ESBL)-
producing isolates have spread worldwide.1,2 These isolates are
often multidrug-resistant, and carbapenems are often regarded as* Corresponding author. Tel.: +33 241354395; fax: +33 241354936.
E-mail address: JeanRalph.ZAHAR@chu-angers.fr (J.-R. Zahar).
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).a major antibacterial drug.3,4 Massive prescription of these drugs
has ecological consequences.5 Indeed it increases the rise and spread
of carbapenemase-producing Enterobacteriaceae6 and the rate of
subsequent multidrug-resistant bacteria-related infections.3,4
Several studies have tried to assess the safety and efﬁcacy
(mortality and length of hospital stay) of the use of non-carbapenem
drugs for the treatment of ESBL-related infections.7–10 Major
studies have been non-randomized and have shown conﬂicting
results.8 In patients with susceptible ESBL-producing Escherichia
coli bloodstream infections (BSI), Rodrı´guez-Ban˜o et al.7 showedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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with carbapenems or beta-lactam/beta-lactam inhibitor (BLBLI)
combinations (including piperacillin–tazobactam (PTZ) and amoxi-
cillin–clavulanate (AAC)). However that cohort study was composed
mainly of patients with bacteraemia originating from the urinary
tract and did not take into account minimum inhibitory concentra-
tions (MICs). Despite theoretical microbial susceptibility (as deﬁned
by the Clinical and Laboratory Standards Institute criteria), recent
studies have reported suboptimal clinical and microbiological
outcomes in patients treated with alternatives to carbapenems
for infections with ESBL-producing strains.11 In this setting, the use
of cephalosporins (as compared to carbapenems) has also been
associated with increased mortality, even when the MIC for
Enterobacteriaceae remains within the susceptible range.12,13
Conversely, the use of ﬂuoroquinolones is also frequently restricted
by antimicrobial co-resistance of ESBL strains.4 Therefore, non-
carbapenem alternatives may be used with caution in selected cases
of infection with ESBL-producing strains, but clear guidelines are
currently lacking.14–16
The primary aims of this observational prospective cohort study
were to identify the rate of non-carbapenem alternative prescrip-
tion and to evaluate the frequency and factors associated with the
omission of de-escalation. The secondary aim was to identify daily
practice factors associated with carbapenem prescription (either
as empirical or as deﬁnitive therapy) in the setting of ESBL
infections.
2. Materials and methods
2.1. Study design
This observational prospective study was performed in two
French university hospitals (Hoˆpital Necker Enfants Malades, Paris,
and Hoˆpital Henri Mondor, Cre´teil) from May 2012 to January
2013. Antimicrobial stewardship teams are well established in
these hospitals, each composed of a pharmacist and a full-time
infectious disease physician, assisted by one or two fellows.
At the time the antimicrobial stewardship team was alerted by
the microbiologist, a ﬁrst consultation (at day 0 or day +1)
consisted of encouraging prescribers to adapt their treatment in
accordance with local recommendations. A second visit was
systematically performed when antimicrobial susceptibility tests
were obtained. An advice and an evaluation were systematically
delivered to improve and adapt antibiotic prescription. De-
escalation was systematically proposed when clinical and micro-
biological data allowed it. Practitioners were free to follow or not
these recommendations.
All consecutive patients (adults and children) treated for ESBL-
producing Enterobacteriaceae (ESBL-PE) infections were included
prospectively. Using a computer-generated alert system, the
antimicrobial stewardship team conducted a systematic post-
prescription review of all carbapenem prescriptions. All ESBL-PE
documented infections were recorded daily by a microbiologist
who notiﬁed the antimicrobial team. During the study period, a
review of all antibiotic prescriptions initiated for ESBL-PE
documented infections was also systematically performed. The
team reviewed all prescriptions successively within the ﬁrst 48 h,
when antimicrobial susceptibility tests were available, and ﬁnally
on day 5. Data collected at inclusion consisted of demographic
characteristics (age, sex), comorbid conditions, Charlson’s weight-
ed index of morbidity, immunodeﬁciency, previously known ESBL
rectal carriage for the last 6 months, and the clinical severity
according to the Bone criteria.17 Immunodeﬁciency was deﬁned as
neoplasia with recent chemotherapy (less than 30 days before
infection), neutropenia (neutrophil count <0.5  109 cells/l), treat-
ment with glucocorticosteroids and/or other immunosuppressantswithin the last month, solid organ or bone marrow transplantation
recipient, or AIDS (CD4 cell count <200/ml, or other evidence of AIDS
as deﬁned by the US Centers for Disease Control and Prevention
(CDC)).18
The primary source of infection was determined according to
the CDC criteria,19 or otherwise deﬁned as primary bacteraemia
with no determined portal of entry.
Bacterial identiﬁcation was performed in both hospitals with
the commercially available Vitek 2 system or with the API 20 E, API
20NE strips (bioMe´rieux, Marcy l’Etoile, France). Microbiological
ESBL diagnosis was carried out according to the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
breakpoints.20 In vitro antimicrobial susceptibility testing was
performed with the disk diffusion method or with the Vitek
2 system in accordance with the guidelines of the Antibiogram
Committee of the French Microbiological Society.21 Clinical
outcome was recorded at hospital discharge.
Two non-mutually exclusive cohorts of patients (receiving
either carbapenems or an alternative) were constructed and
analyzed separately. The empirical therapy cohort (ETC) included
patients during the ﬁrst 24 h following positive microbiological
results (day 0) and the deﬁnitive therapy cohort (DTC) included
patients treated according to MIC results from day 5 until the end
of antimicrobial therapy.
2.2. Alternatives to carbapenems
Third-generation cephalosporins (3GC), PTZ, and cephamycins
were used as carbapenem alternatives, as per EUCAST recommen-
dations. Thus, strains with a MIC <8 mg/l were considered
susceptible to PTZ and strains with a MIC <1 mg/l were considered
susceptible to 3GC.
2.3. Statistical analysis
2.3.1. Descriptive analysis
A descriptive analysis was performed using the median and
interquartile range (IQR) or the mean and standard deviation (SD)
for the quantitative variables, and the number and proportion for
the qualitative variables.
2.3.2. Factors associated with the maintenance of carbapenems
Factors associated with the maintenance of carbapenem
therapy were identiﬁed using both univariate and multivariate
analysis, using a conditional logistic regression model. Analyses
were stratiﬁed on the centre and hospitalization in a ward
dedicated to paediatric care. Associations are reported as the
odds ratio (OR) and 95% conﬁdence interval (CI). Factors
considered for the multivariate model were those with at least
10 events, without missing data, that were non-collinear with
other factors (with a signiﬁcance level <105 ), and associated
with the status (maintenance or withdrawal of carbapenem
therapy) on univariate analysis with a signiﬁcance level (p-
value) less than 0.20. Factors included in the ﬁnal multivariate
model were selected using a forward stepwise selection
procedure based on the Akaike Information Criterion (AIC).
The statistical analysis was performed by T.D. using R program
version 3.02 (R Foundation for Statistical Computing, Vienna,
Austria). This observational study is reported according to the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement.22
3. Results
During the study period, 79 ESBL-PE-related infections were
included. Baseline characteristics of the patients are detailed in
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(IQR 2.15–58.8) years and 36 (46%) patients were children (age <16
years). Fifty-three (67%) infections were nosocomially acquired, 37
(46.8%) were recorded in immunocompromised patients, and 54
(68.4%) patients were known to be previous ESBL rectal carriers.
3.1. Carbapenem prescription as empirical therapy
Antibiotic use is shown in Figure 1. Thirty-four (43.0%) patients
were treated with carbapenems, while 45 patients received an
alternative (BLBLI combination, n = 20; 3GC, n = 18; ﬂuoroquino-
lones, n = 2; amikacin, n = 5).
Factors associated with carbapenem prescription (rather than
an alternative drug) as empirical antibiotic therapy are detailed in
Table 2. As compared to patients hospitalized in medical and surgical
departments, intensive care unit (ICU) patients were treated more
frequently with carbapenems (52.9% vs. 20% respectively; OR 4.5,
95% CI 1.7–12.1). Patients with nosocomial infections were also
more frequently treated empirically with carbapenems (79.41% vs.
57.8%; OR 2.8, 95% CI 1.1–7.8). Last, previously known ESBL-PE rectal
carriage was associated with increased carbapenem prescription
(88.2% vs. 53.3%; OR 6.5, 95% CI 1.9–21.7). Among the 54 patients
previously known to be ESBL-PE rectal carriers, 26 (48%) carriage
strains were considered as resistant to PTZ. Five patients (17.9%)
known by ward physicians to have strains resistant to PTZ were
treated empirically with PTZ for ESBL-PE rectal carriage.
3.2. Carbapenem prescription as deﬁnitive therapy
As compared to other pathogens, E. coli ESBL infections were
more frequently treated with an alternative to carbapenem (ORTable 1
Demographic, clinical, and microbiological data for the 79 study patients
Data: type and parameter No. (%) of patients
Demographic data
Total patients 79 (100)
Male 52 (65.8)
Female 27 (34.1)
Adults 43 (54.4)
Children 36 (45.6)
Age, years, median (IQR) 35.4 (2.15–58.8)
Clinical data
Underlying conditions
Immunosuppressive therapy 26 (33)
Neutropenia 4 (5)
Diabetes mellitus 11 (14)
HIV infection 1 (1)
Ward
Medical department 44 (55.7)
Surgical department 8 (10)
Intensive care unit 27 (34.18)
Charlson score, median (IQR) 3 (1–6)
Nosocomial infection/health care-associated 53 (67)
Community-acquired infection 26 (33)
Origin of infection
Catheter 5 (6.3)
Lung 15 (19)
Urinary tract 42 (53.1)
Skin and soft tissue 4 (5)
Digestive 3 (10)
Bacteraemia 9 (11.4)
Eye 1 (1.2)
Microbiological data
Escherichia coli (%) 34 (43)
Susceptible to alternatives 13 (16.4)
Klebsiella pneumoniae (%) 28 (35.4)
Susceptible to alternatives 9 (11.4)
Klebsiella oxytoca (%) 1 (1.3)
Enterobacter cloacae (%) 16 (20.3)
Susceptible to alternatives 4 (5)
IQR, interquartile range.0.11, 95% CI 0.041–0.324) (Table 3). On day 5, after obtaining the
results of antimicrobial tests, 47 (59.5%) patients were treated with
carbapenems. Among them, 26 (55.3%) were infected with strains
that were susceptible to alternatives. For these patients, the main
reasons for carbapenem maintenance were the following: a history
of prior treatment failure and/or the recurrence of infection (n = 7,
26.9%), poor clinical outcome at day 3 of antimicrobial therapy
(n = 5, 19.2%), underlying immunosuppression (n = 4, 15.4%), the
source of infection (n = 4, 15.4%), and the clinical severity at onset
of infection (n = 3, 11.5%) (Table 4).
3.3. Carbapenem prescription among patients with strains susceptible
to alternatives
Among the 54 previously known ESBL-PE rectal carrier patients,
26 (48%) had strains resistant to PTZ and 28 (52%) had strains
susceptible to alternatives. No risk factor appeared to be associated
with carbapenem prescription as empirical therapy in previously
known ESBL-PE carriers. However, these results must be qualiﬁed
because of the lack of power of the study.
Fifty-eight (73.4%) patients in the deﬁnitive therapy cohort
(DTC) were infected with strains susceptible to alternatives
(according to MIC testing), among whom 47 (81%) were treated
with carbapenems as deﬁnitive therapy. De-escalation was applied
in only 16 (34%) patients who were treated empirically with
carbapenems and infected with PTZ-susceptible strains, without
compromising in-hospital mortality.
4. Discussion
Data regarding the use of non-carbapenem antimicrobial
therapy for ESBL-PE bacteraemia remain scarce.23 Recent retro-
spective studies have reported that de-escalation of empirical
antimicrobial therapy occurs in approximately 50% of patients
with ESBL-producing Enterobacteriaceae-related sepsis,24 but data
are heterogeneous and large ranges of de-escalation incidences
have been reported among studies. Indeed, until very recently
there was no consensus deﬁnition for de-escalation.25–28 Further-
more, in a recent article, Tamma et al.29 reported an increased risk
of death among patients receiving PTZ compared to patients
receiving carbapenem therapy for ESBL-producing Enterobacter-
iaceae-related infections. In this retrospective study, antibiotic de-
escalation was analyzed in 79 consecutive patients with ESBL-
producing Enterobacteriaceae bacteraemia. De-escalation, as a
global management of antibiotic therapy, occurred in 20% of
cases. Several plausible reasons might explain why this rate of
antimicrobial therapy de-escalation is lower than those reported in
many studies.23 First, all of the patients in the present study were
infected with ESBL-producing Enterobacteriaceae strains, thus
reducing the number of possible alternatives to carbapenems.
Second, one-third of the patients were immunocompromised and
two-thirds of the infections were nosocomially acquired, facts that
did not encourage the treating physicians to de-escalate. However,
although the study was not powered for clinical outcomes, de-
escalation appeared to be safe in the present study cohort.
Factors associated with carbapenem maintenance were micro-
biological (i.e., lack of susceptibility to alternatives) in 21 cases
(44.7%) and clinical in 26 cases (55.3%). Among the latter, a history
of treatment failure, relapse of infection, clinical severity at onset
of sepsis, underlying co-morbidities (e.g. immunosuppression),
and polymicrobial infection were the most frequent. In the present
cohort, there was a strong correlation between the type of
pathogen and the physician’s decision to de-escalate or not to de-
escalate antibiotics. According to the multivariate analysis, E. coli-
related infections appeared to be a protective factor against
carbapenem prescription (OR 0.11, 95% CI 0.041–0.324; p = 0.0013)
Figure 1. Antibiotic use for the treatment of ESBL-producing Enterobacteriaceae-related infections. Thirty-six patients continued to receive empirical treatment as the
deﬁnitive therapy (continuous lines), including 27 patients receiving carbapenems and nine patients receiving non-carbapenem antibiotics (all PTZ). Antibiotics were
changed for 43 patients (dashed lines): from adequate non-carbapenem antibiotics to carbapenems (n = 2) (a); from inadequate empirical therapy to carbapenem (n = 26) (b);
from inadequate empirical therapy to adequate non-carbapenem therapy (n = 10). After MIC results were obtained, 15 patients were de-escalated (dashed line) from
carbapenem therapy to adequate non-carbapenem therapy (d).
B. Pilmis et al. / International Journal of Infectious Diseases 39 (2015) 62–67 65in comparison with infections related to other pathogens (e.g.
Klebsiella pneumoniae and Enterobacter cloacae). An explanation for
this could be that these pathogens are more frequently resistant to
alternatives and that there are more data regarding the use of
alternatives for E. coli than for other strains.
There could be multiple reasons behind the slow adoption of
antibiotic de-escalation, including hesitancy to change an effective
antibiotic regimen (especially for ICU patients) and poor understandingTable 2
Factors associated with carbapenem prescription as empirical antibiotic therapy in pat
ETC
Carbapenems
n = 34
Age, years, median (IQR) 46.7 (23–58.3) 
Nosocomial infections (%) 27 (79.41) 
Underlying condition
Immunosuppressive treatment (%) 12 (35.3) 
Neutropenia (ANC <0.5 109/l) (%) 1 (2.9) 
Diabetes mellitus (%) 7 (20.6) 
HIV infection (%) 1 (2.9) 
Hospitalization department
Intensive care unit (%) 18 (52.9) 
Not intensive care unit (%) 16 (47.1) 
Charlson score, median (IQR) 4 (1–6.75) 
Prior ESBL rectal carriage (%) 30 (88.23) 
Source of infection
Catheter (%) 3 (8.8) 
Lung (%) 9 (26.5) 
Urinary tract (%) 15 (44.1) 
Skin and soft tissue (%) 2 (5.9) 
Digestive (%) 2 (5.9) 
Unknown (%) 3 (8.8) 
ESBL, extended-spectrum beta-lactamase; ETC, empirical therapy cohort, univariate ana
neutrophil count.of how and when to de-escalate.26 As demonstrated by Giantsou et al.,
de-escalation should be based on reliable microbiological samples27
and rapid antibiogram testing.30 Currently, the results of standard
microbiological reports (i.e., based on full bacterial identiﬁcation and on
antimicrobial susceptibility tests) rarely reach the treating physician
before 48–72 h after the sampling has been performed.31 In this study,
it was found that previously known ESBL-PE rectal carriage was
associated with increased empirical carbapenem prescription. Oneients with ESBL-related Enterobacteriaceae bacteraemia
ETC
Non-carbapenems
n = 45
OR (95% CI) p-Value
24.7 (2.3–58.9) - 0.878
26 (57.8) 2.8 (1.1–7.8) 0.043
14 (3.1) 1.2 (0.4–3.1) 0.695
3 (6.67) 0.42 (0.04–4.2) 0.455
4 (8.89) 2.7 (0.7–9.9) 0.137
0 (0) - 0.247
9 (20) 4.5 (1.7–12.1) 0.002
36 (80) - -
2 (1–6) - 0.197
24 (53.3) 6.5 (1.9–21.7) 0.001
5 (11.1) 0.77 (0.17–3.49) 0.739
6 (13.3) 2.25 (0.7–7.7) 0.140
21 (46.7) 0.9 (0.36–2.2) 0.822
1 (2.3) 2.7 (0.2–31.6) 0.415
6 (13.3) 0.4 (0.07–2.15) 0.277
6 (13.3) 0.6 (0.14–2.7) 0.532
lysis; OR, odds ratio; CI, conﬁdence interval; IQR, interquartile range; ANC, absolute
Table 3
Factors associated with carbapenem maintenance when, following MIC results, alternative drugs were microbiologically suitable
DTC
Carbapenems
n = 47
DTC
Non-carbapenems
n = 32
Univariate analysis Multivariate analysis
OR (95% CI) p-Value OR (95% CI) p-Value
Age, years, median (IQR) 40.9 (3.1–58.8) 24.7 (13–57.6) 1.02 (0.98–1.06) 0.253 1.08 (1–1.16) 0.027
Gender
Male 30 (63.8) 22 (68.7) 0.96 (0.38–2.47) 0.94 - -
Female 17 (36.2) 10 (31.3) - -
Nosocomial infection (%) 32 (69.5) 21 (63.64) 1.52 (0.58–4.03) 0.39 - -
Hospitalization department
Intensive care unit (%) 18 (38.3) 9 (28.1) 1.96 (0.71–5.4) 0.191 - -
Not intensive care unit (%) 29 (61.7) 23 (71.9) - -
Charlson score, median (IQR) 3.5 (1–6) 2 (1–5) 1.08 (0.94–1.23) 0.266 - -
Bone score, median (IQR) 1 (1–2) 1 (1–2) 1.74 (0.94–3.22) 0.079 3.04 (0.99–9.35) 0.052
Prior ESBL-PE rectal carriage 32 (68) 22 (68.7) 0.96 (0.357–2.58) 0.938 - -
Origin of infection
Urinary tract (%) 22 (46.8) 20 (62.5) 2.48 (0.88–7.01) 0.087 4.35 (0.71–26.7) 0.11
Non urinary tract infection (%) 25 (53.2) 12 (37.5) - - - -
Microorganisms
Escherichia coli (%) 10 (21.3) 24 (75) 0.11 (0.041–0.324) <0.001 0.04 (0.007–0.24) <0.001
Non Escherichia coli (%) 37 (78.7) 8 (25) - -
Initial clinical efﬁcacy (%) 28 (59.5) 23 (71.9) 0.52 (0.189–1.46) 0.216 0.09 (0.01–0.59) 0.012
Initial monotherapy (%) 16 (34) 17 (53.1) 0.46 (0.18–1.17) 0.104 0.1 (0.016–0.62) 0.014
MIC, minimum inhibitory concentration; DTC, deﬁnitive therapy cohort, univariate analysis; OR, odds ratio; CI, conﬁdence interval; IQR, interquartile range; ESBL-PE,
extended-spectrum beta-lactamase-producing Enterobacteriaceae.
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routine use of MIC testing on ESBL rectal colonization strains with
possible susceptibility (according to inhibition zone diameters) to
carbapenem alternatives.
In spite of its multiple strengths, this study also has limitations:
a small number of patients, factors speciﬁc to the institutions (and
the fact that the study was bi centric), and limited study duration.
The results suggest that a large multicentre prospective study of
ESBL-producing Enterobacteriaceae-related infections should be
conducted in order to better characterize the features associated
with carbapenem prescription in daily practice, the rates of non-
carbapenem alternative prescription, and the frequency of
omission of de-escalation despite accurate antibiotic susceptibility
testing. The results of ongoing randomized controlled studies
comparing carbapenems to alternatives for the treatment of ESBL-
producing Enterobacteriaceae-related infections are also eagerly
awaited. Stronger evidence-based data will be required to
convince physicians that, when performed in a standardized
procedure, de-escalation is both safe and effective.
In conclusion, it was found that de-escalation after empirical
treatment with carbapenems for ESBL-producing Enterobacteria-
ceae-related infections was performed for less than half of the
patients. Reasons for not de-escalating included the absence of an
antimicrobial alternative according to antibiotic susceptibility
tests, and also clinical and/or microbiological considerations.
Ethical approval: Ethical approval was not required.Table 4
Reasons for maintaining carbapenem as deﬁnitive therapy
Deﬁnitive therapy cohort of patients treated with carbapenems (%) n = 47
Non-susceptible to alternative (%) 21 (44.7)
Susceptible to alternative (%) 26 (55.3)
Severe sepsis/septic shock (%) 3 (11.5)
Co-morbidities (immunosuppression, etc.) (%) 4(15.4)
Administration facilities (subcutaneous administration) (%) 2 (7.8)
Poor clinical outcome (%) 5 (19.2)
Sepsis source (HCAP, etc.) (%) 4 (15.4)
Polymicrobial infection (%) 1 (3.8)
Relapse or recurrence of the infection (%) 7 (26.9)
HCAP, health care-associated pneumonia.Conﬂict of interest: The authors declare that they have no
competing interests.
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